Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
Using archived tumor samples from individuals with glioblastoma, researchers saw methylation variability at progression, along with potential prognostic hints.
The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
